0001209191-21-006571.txt : 20210201
0001209191-21-006571.hdr.sgml : 20210201
20210201190901
ACCESSION NUMBER: 0001209191-21-006571
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210129
FILED AS OF DATE: 20210201
DATE AS OF CHANGE: 20210201
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Smith Cynthia
CENTRAL INDEX KEY: 0001609480
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36694
FILM NUMBER: 21578265
MAIL ADDRESS:
STREET 1: 508 WRANGLER DRIVE, SUITE 100
CITY: COPPELL
STATE: TX
ZIP: 75019
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Protara Therapeutics, Inc.
CENTRAL INDEX KEY: 0001359931
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 204580525
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 345 PARK AVENUE SOUTH
STREET 2: 3RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10010
BUSINESS PHONE: 646-844-0337
MAIL ADDRESS:
STREET 1: 345 PARK AVENUE SOUTH
STREET 2: 3RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10010
FORMER COMPANY:
FORMER CONFORMED NAME: ArTara Therapeutics, Inc.
DATE OF NAME CHANGE: 20200110
FORMER COMPANY:
FORMER CONFORMED NAME: PROTEON THERAPEUTICS INC
DATE OF NAME CHANGE: 20060420
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-01-29
0
0001359931
Protara Therapeutics, Inc.
TARA
0001609480
Smith Cynthia
C/O PROTARA THERAPEUTICS, INC.
345 PARK AVENUE SOUTH, 3RD FLOOR
NEW YORK
NY
10010
1
0
0
0
Stock Option (Right to Buy)
17.98
2021-01-29
4
A
0
18000
0.00
A
2031-01-28
Common Stock
18000
18000
D
Stock Option (Right to Buy)
17.98
2021-01-29
4
A
0
3750
0.00
A
2031-01-28
Common Stock
3750
21750
D
The shares vest in a series of 36 successive equal monthly installments over the three-year period measured from the date of grant, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control.
The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control.
/s/ Karen Deschaine, Attorney-in-Fact
2021-02-01